Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Hematology | Internal Medicine | Oncology | Journal

Back to Journal Articles

Macrophages’ Association With Survival in Hodgkin’s Studied

Last Updated: March 10, 2010.

 

Greater number of CD68+ macrophages associated with shorter progression-free survival

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
In patients with classic Hodgkin's lymphoma, having a higher number of tumor-associated macrophages is linked to shortened survival, a finding that may assist in risk stratification, according to research published in the March 11 New England Journal of Medicine.

WEDNESDAY, March 10 (HealthDay News) -- In patients with classic Hodgkin's lymphoma, having a higher number of tumor-associated macrophages is linked to shortened survival, a finding that may assist in risk stratification, according to research published in the March 11 New England Journal of Medicine.

Christian Steidl, M.D., of the University of British Columbia in Vancouver, Canada, and colleagues analyzed data from 130 samples taken during lymph-node biopsy from patients with classic Hodgkin's lymphoma. Through gene-expression profiling, the researchers found a gene signature of tumor-associated macrophages that was associated with the failure of primary treatment.

In another cohort of 166 patients, the researchers found that a higher number of CD68+ macrophages was linked to shorter progression-free survival and a greater chance of relapse following autologous hematopoietic stem-cell transplantation. An increased number of CD68+ macrophages outperformed the International Prognostic Score for disease-specific survival. Lack of an increased number of CD68+ cells in patients with limited-stage disease defined a group with a 100-percent rate of long-term disease-specific survival using current treatments.

"The data provided by Steidl et al appear to be the breakthrough we have been looking for by enabling the selection of patients with a particularly poor prognosis (regardless of stage) for aggressive treatment, which can bring more logic to the treatment of this curable cancer," write the authors of an accompanying editorial.

The study was partially supported by a grant from Roche Molecular Systems; a co-author reported financial relationships with Roche Canada and other pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2010 HealthDay. All rights reserved.


Previous: One in Six Americans Ages 14 to 49 Has Herpes Next: Thyroid Hormone Analogue Improves Cholesterol Lowering

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.